FBIO
Fortress Biotech, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-56/100
Last price
2.05
▼ 0.04 (1.91%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2.09
Day high
2.13
Day low
2.02
Volume
219.88K
Market cap
$68.37M
P/E (TTM)
0.74
52W range
2.00 – 4.53
Trailing performance
Returnvs SPY
1W
-6.82%
-8.8%
1M
-24.63%
-25.8%
3M
-31.67%
-36.2%
6M
-12.77%
-30.9%
YTD
-43.99%
-58.2%
1Y
-25.45%
-41.9%
3Y
-52.87%
-135.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FBIO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
7.97M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 22, 26 | JIN DAVID Chief Financial Officer |
STOCK | 400.00K | $0 | Direct |
| Apr 1, 26 | JIN DAVID Chief Financial Officer |
STOCK | 2.97K | $6.46K | Direct |
| Mar 18, 26 | ROSENWALD LINDSAY A Chief Executive Officer |
STOCK | 475.42K | $0 | Direct |
| Mar 18, 26 | WEISS MICHAEL S Officer and Director |
STOCK | 475.42K | $0 | Direct |
| Dec 31, 25 | LOBELL JONAH JAY Director |
STOCK | 27.32K | $0 | Direct |
| Dec 31, 25 | HOENLEIN MALCOLM Director |
STOCK | 27.32K | $0 | Direct |
| Dec 31, 25 | HARVEY JIMMIE Director |
STOCK | 27.32K | $0 | Direct |
| Dec 31, 25 | KLEIN DOV Director |
STOCK | 27.32K | $0 | Direct |
| Dec 31, 25 | LORENZ KEVIN R. Director |
STOCK | 27.32K | $0 | Direct |
| Oct 1, 25 | JIN DAVID Chief Financial Officer |
STOCK | 2.71K | $6.94K | Direct |
| Apr 1, 25 | JIN DAVID Chief Financial Officer |
STOCK | 5.00K | $7.80K | Direct |
| Dec 31, 24 | ROSENWALD LINDSAY A Chief Executive Officer |
STOCK | 454.15K | $0 | Direct |
| Dec 31, 24 | WEISS MICHAEL S Officer and Director |
STOCK | 454.15K | $0 | Direct |
| Dec 31, 24 | LOBELL JONAH JAY Director |
STOCK | 49.38K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HARVEY JIMMIE |
Director | 146.70K | Stock Award(Grant) |
HOENLEIN MALCOLM |
Director | 115.75K | Stock Award(Grant) |
JIN DAVID |
Chief Financial Officer | 1.65M | Stock Award(Grant) |
KLEIN DOV |
Director | 130.10K | Stock Award(Grant) |
LOBELL JONAH JAY |
Director | 192.40K | Stock Award(Grant) |
LORENZ KEVIN R. |
Director | 101.01K | Stock Award(Grant) |
LU LUCY |
Director | 61.27K | Stock Award(Grant) |
ROSENWALD LINDSAY A |
Chief Executive Officer | 4.59M | Stock Award(Grant) |
WEISS MICHAEL S |
Officer and Director | 2.28M | Stock Award(Grant) |
Fundamentals
Market cap$68.37M
Enterprise value$-32.94M
Revenue (TTM)$68.47M
Gross profit$43.32M
EBITDA$-24.98M
Net income$103.37M
EPS (TTM)$2.76
Free cash flow$-17.14M
Total cash$196.58M
Total debt$53.32M
Book value / share$4.93
Shares outstanding33.35M
Float21.44M
Short % of float19.81%
Dividend yield0.00%
Beta (5Y)1.25
Valuation & profitability ratios
Trailing P/E0.74
Forward P/E-1.16
PEG ratio—
Price / sales—
Price / book0.42
EV / revenue-0.48
EV / EBITDA1.32
Gross margin63.28%
Operating margin-53.46%
Profit margin163.32%
Return on equity115.98%
Return on assets-7.76%
Debt / equity25.87
Current ratio3.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $63.26M | $57.67M | $84.51M | $75.74M | +9.7% |
| Operating revenue | $61.24M | $56.67M | $64.99M | $73.07M | +8.1% |
| Cost of revenue | $20.92M | $20.88M | $22.89M | $30.77M | +0.2% |
| Gross profit | $42.34M | $36.80M | $61.62M | $44.97M | +15.1% |
| Research & development | $11.90M | $56.88M | $106.07M | $134.88M | -79.1% |
| Selling, general & admin | $96.40M | $87.73M | $90.98M | $113.66M | +9.9% |
| Total operating expense | $112.56M | $148.04M | $200.82M | $248.53M | -24.0% |
| Operating income | -$70.22M | -$111.24M | -$139.20M | -$203.56M | +36.9% |
| Net interest income | -$7.62M | -$10.84M | -$12.31M | -$12.24M | +29.7% |
| Pre-tax income | -$33.53M | -$120.54M | -$153.63M | -$213.46M | +72.2% |
| Tax provision | -$620.00K | $312.00K | $521.00K | $449.00K | -298.7% |
| Net income | $6.82M | -$46.00M | -$60.64M | -$86.58M | +114.8% |
| Net income to common | -$1.88M | -$55.89M | -$68.67M | -$94.61M | +96.6% |
| Basic EPS | -0.07 | -2.69 | -8.47 | -14.55 | +97.4% |
| Diluted EPS | -0.07 | -2.69 | -8.47 | -14.55 | +97.4% |
| EBIT | -$24.83M | -$108.95M | -$141.72M | -$203.05M | +77.2% |
| EBITDA | -$20.16M | -$104.49M | -$135.72M | -$193.69M | +80.7% |
| Basic shares | 27.90M | 20.78M | 8.11M | 5.92M | +34.2% |
| Diluted shares | 27.90M | 20.78M | 8.11M | 5.92M | +34.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.38M | $57.26M | $80.93M | $178.27M | — | +38.6% |
| Cash & short-term investments | $79.38M | $57.26M | $80.93M | $178.27M | — | +38.6% |
| Accounts receivable | $29.78M | $10.23M | $15.22M | $28.21M | — | +191.1% |
| Inventory | $9.62M | $14.43M | $10.21M | $14.16M | — | -33.3% |
| Total current assets | $123.84M | $90.37M | $117.02M | $230.43M | — | +37.0% |
| Property, plant & equipment | $14.82M | $17.12M | $23.50M | $33.01M | — | -13.4% |
| Goodwill & intangibles | $27.61M | $31.86M | $20.29M | $27.20M | — | -13.4% |
| Total assets | $185.55M | $144.22M | $167.53M | $294.30M | — | +28.7% |
| Total current liabilities | $49.74M | $71.40M | $84.91M | $127.72M | — | -30.3% |
| Current debt | — | $625.00K | $3.00M | $10.18M | $5.32M | — |
| Long-term debt | $59.50M | $57.96M | $60.86M | $93.14M | — | +2.7% |
| Total debt | $74.30M | $75.96M | $84.66M | $127.34M | — | -2.2% |
| Total liabilities | $123.36M | $145.87M | $165.94M | $244.28M | — | -15.4% |
| Retained earnings | -$734.05M | -$740.87M | -$694.87M | -$634.23M | — | +0.9% |
| Shareholder equity | $49.87M | $22.74M | $22.54M | $41.72M | — | +119.3% |
| Working capital | $74.10M | $18.97M | $32.11M | $102.72M | — | +290.6% |
| Net tangible assets | $22.27M | -$9.13M | $2.26M | $14.52M | — | +344.0% |
| Shares issued | 31.36M | 27.91M | 15.09M | 7.37M | — | +12.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$32.91M | -$120.86M | -$154.15M | -$213.91M | — | +72.8% |
| Depreciation & amortisation | $4.66M | $4.46M | $6.00M | $9.35M | — | +4.4% |
| Stock-based compensation | $28.74M | $32.62M | $17.03M | $22.99M | — | -11.9% |
| Change in working capital | -$25.10M | -$8.13M | -$12.52M | -$715.00K | — | -208.8% |
| Operating cash flow | -$65.78M | -$80.19M | -$128.22M | -$179.40M | — | +18.0% |
| Capital expenditure | — | -$15.00M | -$8.10M | -$3.06M | -$16.35M | — |
| Investing cash flow | $10.12M | -$15.00M | -$2.10M | -$22.93M | — | +167.5% |
| Share buybacks | -$265.00K | $0 | -$400.00K | -$1.20M | — | — |
| Dividends paid | -$664.00K | -$4.71M | -$8.77M | -$8.78M | — | +85.9% |
| Financing cash flow | $77.44M | $70.64M | $32.74M | $75.32M | — | +9.6% |
| Free cash flow | -$65.78M | -$95.19M | -$136.32M | -$182.46M | — | +30.9% |
| End cash position | $80.60M | $58.81M | $83.36M | $180.95M | — | +37.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $18.72M | $16.04M | $16.08M | $17.63M | $16.41M | — | +16.7% |
| Operating revenue | $17.84M | $15.92M | $16.07M | $17.02M | $15.01M | — | +12.0% |
| Cost of revenue | $6.14M | $6.22M | $5.44M | $5.75M | $4.94M | — | -1.2% |
| Gross profit | $12.57M | $9.82M | $10.64M | $11.88M | $11.47M | — | +28.1% |
| Research & development | $805.00K | $540.00K | -$367.00K | $208.00K | $8.13M | — | +49.1% |
| Selling, general & admin | $20.81M | $15.89M | $14.73M | $17.41M | $38.76M | — | +30.9% |
| Total operating expense | $22.58M | $17.56M | $15.43M | $18.69M | $47.95M | — | +28.6% |
| Operating income | -$10.01M | -$7.74M | -$4.79M | -$6.81M | -$36.47M | — | -29.3% |
| Net interest income | $105.00K | -$2.80M | -$1.40M | -$2.01M | -$1.90M | — | +103.8% |
| Pre-tax income | $922.00K | $142.29M | -$6.21M | $8.85M | -$11.65M | — | -99.4% |
| Tax provision | $320.00K | $5.13M | -$816.00K | $26.00K | $0 | — | -93.8% |
| Net income | -$468.00K | $110.37M | -$3.94M | $5.85M | $15.49M | — | -100.4% |
| Net income to common | -$2.48M | $108.36M | -$6.20M | $3.67M | $13.36M | — | -102.3% |
| Basic EPS | -0.08 | 3.44 | — | 0.13 | 0.50 | -0.48 | -102.3% |
| Diluted EPS | -0.08 | 2.82 | — | 0.11 | 0.45 | -0.48 | -102.8% |
| EBIT | $2.17M | $144.06M | -$4.50M | $11.27M | -$9.58M | — | -98.5% |
| EBITDA | $3.24M | $145.28M | -$3.35M | $12.43M | -$8.42M | — | -97.8% |
| Basic shares | 31.79M | 31.54M | — | 27.24M | 26.88M | 26.45M | +0.8% |
| Diluted shares | 31.79M | 38.41M | — | 33.10M | 29.82M | 26.45M | -17.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $196.58M | $255.84M | $79.38M | $86.22M | $74.39M | — | -23.2% |
| Cash & short-term investments | $196.58M | $255.84M | $79.38M | $86.22M | $74.39M | — | -23.2% |
| Accounts receivable | $36.25M | $24.99M | $29.78M | $17.98M | $15.64M | — | +45.0% |
| Inventory | $8.16M | $9.29M | $9.62M | $11.82M | $12.85M | — | -12.2% |
| Total current assets | $245.51M | $295.48M | $123.84M | $118.50M | $110.40M | — | -16.9% |
| Property, plant & equipment | $13.77M | $14.25M | $14.82M | $14.93M | $15.52M | — | -3.4% |
| Goodwill & intangibles | $25.51M | $26.48M | $27.61M | $28.67M | $29.73M | — | -3.7% |
| Total assets | $316.71M | $356.87M | $185.55M | $181.41M | $159.90M | — | -11.3% |
| Total current liabilities | $62.02M | $103.39M | $49.74M | $54.07M | $57.52M | — | -40.0% |
| Current debt | $5.00M | $2.50M | — | $5.63M | $3.75M | $1.88M | +100.0% |
| Long-term debt | $34.60M | $36.88M | $59.50M | $47.77M | $50.03M | — | -6.2% |
| Total debt | $53.32M | $53.63M | $74.30M | $68.29M | $69.22M | — | -0.6% |
| Total liabilities | $110.63M | $154.50M | $123.36M | $116.22M | $122.51M | — | -28.4% |
| Retained earnings | -$624.15M | -$623.68M | -$734.05M | -$730.12M | -$735.97M | — | -0.1% |
| Shareholder equity | $164.14M | $162.21M | $49.87M | $55.86M | $43.92M | — | +1.2% |
| Working capital | $183.49M | $192.09M | $74.10M | $64.44M | $52.88M | — | -4.5% |
| Net tangible assets | $138.63M | $135.73M | $22.27M | $27.19M | $14.19M | — | +2.1% |
| Shares issued | 33.31M | 33.19M | 31.36M | 31.01M | 29.75M | — | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $602.00K | $137.16M | -$5.40M | $8.83M | -$11.65M | -99.6% |
| Depreciation & amortisation | $1.06M | $1.22M | $1.16M | $1.16M | $1.16M | -12.8% |
| Stock-based compensation | $2.88M | $1.76M | $2.46M | $3.20M | $16.79M | +63.9% |
| Change in working capital | -$53.64M | $55.79M | -$10.80M | -$4.53M | -$7.48M | -196.1% |
| Operating cash flow | -$59.28M | $203.85M | -$12.54M | -$6.11M | -$27.56M | -129.1% |
| Investing cash flow | -$79.00K | $0 | $0 | $2.87M | $6.09M | — |
| Share buybacks | $0 | -$14.34M | $0 | $0 | -$115.00K | +100.0% |
| Dividends paid | -$141.00K | $0 | -$166.00K | -$166.00K | -$166.00K | — |
| Financing cash flow | $91.00K | -$27.39M | $5.71M | $15.07M | $4.52M | +100.3% |
| Free cash flow | -$59.36M | $203.85M | -$12.54M | -$6.11M | -$27.56M | -129.1% |
| End cash position | $197.80M | $257.06M | $80.60M | $87.44M | $75.61M | -23.1% |
Options analytics
Put / call volume
5.08
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
+22.0% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
13
Contracts, this expiry
Put volume
66
Contracts, this expiry
Heaviest call OI
7.50
2 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.20 | -0.08 | +60.0% |
| Mar 2026 | -0.22 | 2.82 | +1,381.8% |
| Dec 2025 | 0.11 | -0.21 | -290.9% |
| Sep 2025 | -0.63 | 0.11 | +117.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.27 | 1 | $21.57M | +22.4% |
| Next quarter | -0.25 | 1 | $22.46M | +39.7% |
| Current year | 2.55 | 1 | $78.79M | +24.6% |
| Next year | -1.00 | 1 | $113.25M | +43.7% |
Analyst targets & ownership
Mean target$5.00
High target$5.00
Low target$5.00
Implied upside143.90%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders23.90%
Held by institutions31.43%
Institutions holding70
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.16
-5.31% from price
SMA 20
2.34
-12.26% from price
SMA 50
2.65
-22.51% from price
SMA 100
2.81
-27.10% from price
SMA 200
2.96
-30.68% from price
EMA 12
2.20
-6.85% from price
EMA 26
2.38
-13.89% from price
EMA 50
2.56
-20.01% from price
RSI (14)
26.4
Oversold
MACD (12,26,9)
-0.18
Hist -0.02
ATR (14)
0.09
4.49% of price
Realised vol 30D
31.2%
Annualised
Bollinger upper
2.72
20, 2σ
Bollinger lower
1.95
20, 2σ
50 / 200 cross
Death
2.65 vs 2.96
Trend bias
Below 200
-30.68%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.21
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
31.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-53.7%
Peak to trough
Max drawdown 5Y
-97.6%
Peak to trough
ATR 14
0.09
4.49% of price
Beta (reported)
1.25
5Y monthly, from filing
Short interest
Shares short
5.11M
Prior 5.58M
Change vs prior
-8.4%
Shorts covering
% of float
19.81%
Elevated
% of shares out
15.31%
Against total outstanding
Days to cover
13.8
Crowded exit
Float
21.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 11, 25 | Roth MKM | MAINTAINED | Buy | Buy |
| Nov 18, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 19, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 20, 24 | Cantor Fitzgerald | MAINTAINED | — | Overweight |
| May 16, 24 | Roth MKM | MAINTAINED | Buy | Buy |
| Mar 19, 24 | Alliance Global Partners | INITIATED | — | Buy |
| Nov 29, 23 | Roth MKM | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:15
Split dateOct 10, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-06-23
Periodic Financial Reports
10-Q · 2026-05-14
Proxy Statements
DEFA14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-03-30
Corporate Changes & Voting Matters
8-K · 2026-02-23
Headlines
Journey Medical Corporation to Participate in September 2026 Investor Conferences
GlobeNewswire · 29d ago
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 29d ago
Fortress Biotech, Inc. Q2 2026 Earnings Call Summary
Moby · 54d ago
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
Fortress Biotech: Q2 Earnings Snapshot
Associated Press · 54d ago
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 55d ago
Fortress Biotech Q2 Earnings Call Highlights
MarketBeat · 55d ago
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.